Background. Haemodialysis (HD) catheter-related bloodstream infections (CRBSIs) are a major complication of long-term catheter use in HD. This study identified the epidemiology of HD CRBSIs and to aid in the choice of empiric antibiotics therapy given to patients with HD CRBSIs. Methods. Patients with HD CRBSIs were identified. Their blood cultures were performed according to standard sterile technique. Specimens were sent to the microbiology lab for culture and sensitivity testing. Results were tabulated in antibiograms. Results. 18 patients with a median age of 61.0 years (IQR: 51.5–73.25) were confirmed to have HD CRBSIs based on our study criteria. Eight (44.4%) patients had gram-negative infections, 7 (38.9%) patients gram-positive infections, and 3 (16.7%) patients had polymicrobial infections. We noted that most of the gram-negative bacteria were sensitive to ceftazidime. Unfortunately, cloxacillin resistance was high among gram-positive organisms. Coagulase-negative Staphylococcus and Bacillus sp. were the most common gram-positive organisms and they were sensitive to vancomycin. Conclusion. Our study revealed the increased incidence of gram-negative organism in HD CRBSIs. Antibiogram is an important tool in deciding empirical antibiotics for HD CRBSIs. Tailoring your antibiotics accordingly to the antibiogram can increase the chance of successful treatment and prevent the emergence of bacterial resistance. 1. Introduction Chronic kidney disease (CKD) is a major public health burden [1]. The contribution of CKD to the global burden of disease may be underestimated due to the lack of significant importance in certain kidney disease classifications and failure to realize the relationship of CKD with cardiovascular disease [1]. The prevalence of end-stage renal disease (ESRD) is increasing exponentially worldwide. USA, Japan, and Taiwan had the highest rate of prevalence of ESRD [2]. In Malaysia, dialysis is the main modality of renal replacement therapy. There were about 26,000 patients on dialysis in 2011 with the prevalence of 900 per million populations [3]. Haemodialysis (HD) accounts for about 89% of dialysis patients and most of them were accepted to centre HD [4]. Unfortunately, not all patients enter HD program with a native vascular access. Many patients still presented late and HD access catheter, either cuffed or noncuffed catheters, is needed to perform HD. The use of HD catheter had increased from 3% in 2002 to 8.1% in 2011 of all vascular accesses [5]. We cannot argue that HD catheter plays a very important role in the treatment of
References
[1]
A. Schieppati and G. Remuzzi, “Chronic renal diseases as a public health problem: epidemiology, social, and economic implications,” Kidney International, Supplement, vol. 68, supplement 98, pp. S7–S10, 2005.
[2]
U S Renal Data System, “USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States,” National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md, USA, vol. 2, no. 12, pp. 348, 2012.
[3]
Y. N. Lim, L. M. Ong, B. L. Goh, and D. G. Lee, “Nineteen report of Malaysian Dialysis and Transplantation Registry 202: all renal replacement therapy in Malaysia. Kuala Lumpur,” The National Renal Registry, vol. 1, pp. 1–3, 2012.
[4]
Y. N. Lim, L. M. Ong, A. Ghazali, and D. G. Lee, “Nineteen report of Malaysian Dialysis and Transplantation Registry 2012: dialysis in Malaysia. Kuala Lumpur,” The National Renal Registry, vol. 2, pp. 5–31, 2012.
[5]
C. C. Tan, S. F. K. Shahnaz, A. Rafidah, and Z. S. Norleen, “Nineteen Report of Malaysian Dialysis and Transplantation Registry 2012: haemodialysis practises. Kuala Lumpur,” The National Renal Registry, vol. 11, pp. 140–160, 2012.
[6]
B. C. Astor, J. A. Eustace, N. R. Powe, M. J. Klag, N. E. Fink, and J. Coresh, “Type of vascular access and survival among incident hemodialysis patients: the choices for healthy outcomes in caring for ESRD (CHOICE) Study,” Journal of the American Society of Nephrology, vol. 16, no. 5, pp. 1449–1455, 2005.
[7]
R. Vanholder, B. Canaud, R. Fluck et al., “Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP),” NDT Plus, vol. 3, no. 3, pp. 234–246, 2010.
[8]
S. Joshi, “Hospital antibiogram: a necessity,” Indian Journal of Medical Microbiology, vol. 28, no. 4, pp. 277–280, 2010.
[9]
E. Bouza, N. Alvarado, L. Alcalá, M. J. Pérez, C. Rincón, and P. Mu？oz, “A randomized and prospective study of 3 procedures for the diagnosis of catheter-related bloodstream infection without catheter withdrawal,” Clinical Infectious Diseases, vol. 44, no. 6, pp. 820–826, 2007.
[10]
R. Vanholder, B. Canaud, R. Fluck et al., “Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP),” NDT Plus, vol. 3, no. 3, pp. 234–246, 2010.
[11]
G. Jean, B. Charra, C. Chazot et al., “Risk factor analysis for long-term tunneled dialysis catheter-related bacteremias,” Nephron, vol. 91, no. 3, pp. 399–405, 2002.
[12]
G. R. Qasaimeh, S. E. Qaderi, G. A. Omari, and M. A. Badadweh, “Vascular access infection among hemodialysis patients in northern Jordan: incidence and risk factors,” Southern Medical Journal, vol. 101, no. 5, pp. 508–512, 2008.
[13]
T. F. Saad, “Bacteremia associated with tunneled, cuffed hemodialysis catheters,” American Journal of Kidney Diseases, vol. 34, no. 6, pp. 1114–1124, 1999.
[14]
S. J. Schwab and G. Beathard, “The hemodialysis catheter conundrum: hate living with them, but can't live without them,” Kidney International, vol. 56, no. 1, pp. 1–17, 1999.
[15]
I. Alexandraki, R. Sullivan, R. Zaiden et al., “Blood culture isolates in hemodialysis vascular catheter-related bacteremia,” American Journal of the Medical Sciences, vol. 336, no. 4, pp. 297–302, 2008.
[16]
E. Velasco, R. Byington, C. S. A. Martins, M. Schirmer, L. C. M. Dias, and V. M. S. C. Gon？alves, “Bloodstream infection surveillance in a cancer centre: a prospective look at clinical microbiology aspects,” Clinical Microbiology and Infection, vol. 10, no. 6, pp. 542–549, 2004.
[17]
E. Velasco, R. Byington, C. A. S. Martins, M. Schirmer, L. M. C. Dias, and V. M. S. C. Gon？alves, “Comparative study of clinical characteristics of neutropenic and non-neutropenic adult cancer patients with bloodstream infections,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 25, no. 1, pp. 1–7, 2006.
[18]
D. Maki and L. A. Mermel, “Infections due to infusion therapy,” in Hospital Infections, J. Bennett and P. Brachman, Eds., pp. 689–724, Lippincott-Raven, Philadelphia, Pa, USA, 1998.
[19]
I. B. Alexandraki and D. T. Plott, “Hemodialysis vascular catheter-related bacteremia: five year epidemiologic shift in organism isolates,” Journal of the American Society of Nephrology, vol. 16, p. 435A, 2005.
[20]
J. L. Nouwen, J. J. Wielenga, H. van Overhagen et al., “Hickman catheter-related infections in neutropenic patients: insertion in the operating theater versus insertion in the radiology suite,” Journal of Clinical Oncology, vol. 17, no. 4, pp. 1304–1311, 1999.
[21]
M. K. Lacy, N. E. Klutman, R. T. Horvat, and A. Zapantis, “Antibiograms: new NCCLS guidelines, development, and clinical application,” Hospital Pharmacy, vol. 39, no. 6, pp. 542–553, 2004.
[22]
A. Zapantis, M. K. Lacy, R. T. Horvat et al., “Nationwide antibiogram analysis using NCCLS M39-A guidelines,” Journal of Clinical Microbiology, vol. 43, no. 6, pp. 2629–2634, 2005.
[23]
A. H. Abdul Gafor and P. Petrick, PPUKM Antibiotic Guideline 2008: Clinical Approach to Empirical Choice of Antimicrobial Therapy: IV Line Infection, Percetakan Nasional Malaysia Berhad, 2008.
